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Bringing home baby
Sensitive, skilled fetal and infant care
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At home on the Plaza
This spring, a mallard family took up residence in the 
Maya Lin-designed water feature on the Ellen S. Clark 
Hope Plaza. The parents and ducklings proved a 
popular attraction, often drawing crowds — many 
taking photos with their cameras and phones —  
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mong the most common pediatric 
injuries seen in emergency rooms 
are fractures that occur when  
children fall and try to catch themselves  
with an outstretched hand.
For many, that tumble on the play-
ground, around the bases or off a bunk bed 
results in a buckle fracture, a forearm injury 
traditionally treated with a cast.
But new research from the School of 
Medicine shows that removable splints are 
clearly preferred by patients and their par-
ents, building on earlier findings that such 
splints are just as effective as casts.
“Our goal is to manage these fractures 
in a manner that allows healing while 
maximizing comfort and convenience, 
yet minimizing disruptions in children’s 
active lifestyles,” says senior author Janet 
D. Luhmann, MD, an associate professor of 
pediatrics and physician in the emergency 
department at St. Louis Children’s Hospital.
 “Traditionally, forearm buckle fractures 
have been managed with casts, which can 
be heavy, uncomfortable and, in the sum-
mer, hot and cumbersome. Without an 
expensive liner, children can’t get them wet, 
which results in significant inconvenience 
regarding swimming and hygiene.”
The new findings, coupled with earlier 
research into the effectiveness of splints 
versus casts, have led to a change in the 
standard treatment of these type of frac-
tures at St. Louis Children’s. Now, prefabri-
cated splints are the chosen treatment.
Further, absent pain experienced by 
patients, no longer is it recommended that 
they follow up with orthopedic surgeons 
and possibly undergo more X-rays. Rather, 
explains Kristine G. Williams, MD, the study’s 
lead author, children can be seen by their 
pediatricians two or three weeks later.
The researchers’ findings are available 
online in Pediatric Emergency Care.
Children’s bones, when compared with 
the bones of adults, are less dense, more 
porous and more likely to bend than break. 
Buckle fractures are inherently stable and are 
at low risk for displacement and complete 
breakage, so they tend to heal well with 
minimal intervention. 
Study findings, authors say, show that 
when treating uncomplicated buckle frac-
tures near the wrist, splints are preferred by 
patients and their parents — in addition to 
being easier, less expensive and less time-
consuming than casts.
‘’Parents rated the splint higher in almost 
all categories,” says Williams, an assistant 
professor of pediatrics who treats patients at 
St. Louis Children’s. “They tended to say they 
would definitely choose the splint again over 
a cast if they had a similar kind of injury.”
Splints preferred over  
casts for forearm  
buckle fractures
It’s a wrap!
A significant percentage 
of emergency department 
visits involve children 
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Nanoparticles carrying a toxin found in bee venom can 
destroy human immunodeficiency virus (HIV) while leav-
ing surrounding cells unharmed, researchers at the School 
of Medicine have shown. e finding is an important step 
toward developing a vaginal gel that may prevent the spread 
of HIV, the virus that causes AIDS.
“Our hope is that in places where HIV is running rampant, 
people could use this gel as a preventive measure to stop the 
initial infection,” says Joshua L. Hood, MD, PhD, a research 
instructor in medicine.
e study appears in the March issue of Antiviral erapy.
Bee venom contains a toxin called melittin that can poke 
holes in the protective envelope that surrounds HIV and 
other viruses. Large amounts of free melittin can cause a lot 
of damage. In addition to anti-viral therapy, the paper’s senior 
author, Samuel A. Wickline, MD, the James R. Hornsby 
Family Professor of Biomedical Sciences, has shown melittin-
loaded nanoparticles to be effective in killing tumor cells.
e new study shows that melittin loaded onto these 
nanoparticles does not harm normal cells because Hood 
added protective bumpers to the nanoparticle surface.  
When the nanoparticles come into contact with normal  
cells, which are much larger, the particles simply bounce off.  
HIV, on the other hand, is even 
smaller than the nanoparticle,  
so HIV fits between the bumpers  
and makes contact with the sur-
face of the nanoparticle, where  
the bee toxin awaits.
“Melittin on the nanoparticles 
fuses with the viral envelope,” 
Hood says. “e melittin forms 
little pore-like attack complexes 
and ruptures the envelope, stripping it off the virus.”
Hood says an advantage of this is that the nanoparticle 
attacks an essential part of the virus’ structure. In contrast, 
most anti-HIV drugs inhibit the virus’ ability to replicate,  
but this does nothing to stop initial infection.
“We are attacking an inherent physical property of HIV,” 
Hood says. “eoretically, there isn’t any way for the virus  
to adapt to that. e virus has to have a protective coat, a 
double-layered membrane that covers the virus.”
Beyond prevention in the form of a vaginal gel, Hood also 
sees potential for using nanoparticles with melittin as therapy 
for existing HIV infections, especially those that are drug-
resistant. e nanoparticles could be injected intravenously 
and should be able to clear HIV from the bloodstream.
Newborn screening  On July 9 at St. Louis Children’s 
Hospital, Missouri Governor Jay Nixon signed a bill  integrating pulse 
oximetry into routine newborn testing for critical congenital heart 
disease. A pulse oximeter, a small cuff that fits around a baby’s hand 
or foot, reads the level of oxygen in the blood, along with heart rate. 
Sherrie M. Hauft, MD, Cynthia M. Ortinau, MD, and George F. Van Hare, 








Powderly named director of  
Institute for Public Health
William G. Powderly, MD, the J. William Campbell 
Professor of Medicine at the School of Medicine, has been 
named director of the Institute for Public Health (IPH), 
effective July 1, 2013. Powderly succeeds founding director 
Edward F. Lawlor, PhD, dean of the Brown School and the 
William E. Gordon Distinguished 
Professor.
Graham A. Colditz, MD, DrPH, 
the Niess-Gain Professor of Surgery, 
continues to serve as deputy director.
“Washington University’s Institute 
for Public Health has flourished 
under the leadership of Eddie Lawlor,” 
says Chancellor Mark S. Wrighton. 
“Bill Powderly is the perfect person 
to take the Institute to the next level, 
and I’m grateful he has taken on this 
leadership role.” 
 “I view my role as building on 
what Eddie Lawlor and Graham have 
done,” Powderly says. He oversees all five centers and initia-
tives of IPH. “I look forward to working with Graham and 
the other center directors.”
Powderly is co-director of the Division of Infectious 
Diseases at the School of Medicine and director of the 
Center for Global Health at IPH.
Bee venom kills HIV, leaves  
normal cells unharmed














William G. Powderly, MD
  
The findings from this 
study could apply to other 
viruses as well, including 
hepatitis B and C, which 
also rely on a protective 
envelope.
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A key brain structure that regulates emotions works differ-
ently in preschoolers with depression compared with their 
healthy peers, new research at the School of Medicine shows.
e differences, measured using functional magnetic 
resonance imaging (fMRI), provide the earliest evidence yet 
of changes in brain function in young children with depres-
sion. e researchers say the findings could lead to ways to 
identify and treat depressed children earlier in the course  
of the illness, potentially preventing future problems.
“e findings really hammer home that these kids are 
suffering from a very real disorder that requires treatment,” 
said lead author Michael S. Gaffrey, PhD, assistant professor 
of psychiatry. “We believe this study demonstrates that there 
are differences in the brains of these very young children and 
that they may mark the beginnings of a lifelong problem.”
e study is published in the July issue of the Journal of 
the American Academy of Child & Adolescent Psychiatry.
Depressed preschoolers had elevated activity in the brain’s 
amygdala, an almond-shaped set of neurons important in 
processing emotions. Earlier imaging studies identified simi-
lar changes in the amygdala region in adults, adolescents  
and older children with depression, but none had looked  
at preschoolers.
For the new study, sci-
entists from Washington 
University’s Early Emotional 
Development Program stud-
ied 54 children ages 4 to 6. 
Before the study began, 23 
of them had been diagnosed 
with depression. e other 
31 had not. None had taken 
antidepressant medication. 
While in the fMRI, the 
children looked at pictures 
of people whose facial 
expressions conveyed par-
ticular emotions — happy, 
sad, fearful and neutral. 
“e amygdala region 
showed elevated activity when  
the depressed children viewed pictures of people’s faces,” 
says Gaffrey. “We saw the same elevated activity, regardless 
of the type of faces the children were shown.”
e depressed preschoolers’ responses were somewhat  
different from those previously seen in adults, where the 
amygdala responds more to negative expressions of emotion.
Brain differences seen in 
depressed preschoolers 
The first study of children so young























anks to a grant from the St. Louis-based Edward 
Mallinckrodt Jr. Foundation, 21 physician scientist trainees  
in two clinical departments — Medicine and Pediatrics —  
at the School of Medicine will receive research support.
Physician scientist trainees graduate with combined  
medical and doctoral degrees and usually pursue faculty  
positions that allow them to treat patients and conduct  
laboratory research.
Victoria J. Fraser, MD, the Adolphus Busch Professor and 
head of the Department of Medicine, says the Mallinckrodt 
Foundation gi comes at a crucial 
time, given the current cuts to 
National Institutes of Health (NIH) 
funding. 
e grant, says Stuart A. Kornfeld, 
MD, co-director of the physician sci-
entist training program, “will allow a 
major expansion of these programs.”
e gi is being given in honor of the late Oliver M. 
Langenberg, who led the Mallinckrodt Foundation for more 
than 50 years. e physician scientist training programs 
in medicine and pediatrics will be renamed the Oliver 
Langenberg Physician Scientist Training Program.
Alan L. Schwartz, MD, PhD, the Harriet B. Spoehrer 
Professor and head of the Department of Pediatrics, says that 
the gi is a perfect way to honor Langenberg, who placed 
great value on developing future leaders. e Mallinckrodt 
Foundation’s grants to the School of Medicine have totaled 
$14.6 million.















The grant expands the  
support of physician  
scientist trainees from 
three to 21 each year.
Palmquist receives Dean’s Award   Kristin 
E. Palmquist, right, nurse coordinator in the Washington University 
Infectious Diseases Clinic, talks with co-workers Henry Westerfield 
and Amber Gase, both medical assistants at the clinic. Palmquist 
was awarded the Dean’s Distinguished Service Award, the School of 
Medicine’s highest honor for staff.  “She goes above and beyond the 
call of duty on a daily basis to help provide world-class care,” wrote 
Lori Watkins, the division’s nurse manager.
Brain scans of preschoolers with depression 
revealed elevated activity in the amygdala. 
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cientists have decoded the genome 
of the western painted turtle, one of 
the most abundant turtles on Earth, 
finding clues to its longevity and ability to 
survive without oxygen during winters spent 
hibernating in ice-covered ponds.
Understanding the mechanisms turtles 
use to protect the heart and brain from 
oxygen deprivation may one day improve 
treatments for heart attacks or strokes, the 
researchers say. Both can lead to severe dis-
ability or death within minutes in patients 
deprived of oxygen. 
The research team includes scientists at 
Washington University School of Medicine, 
the University of California at Los Angeles,  
Saint Louis University and other institutions. 
Their analysis is now available online in 
Genome Biology.
New data confirm that the turtles’ pace of 
evolution parallels their speed on the ground. 
It’s exceedingly slow, about one-third of the 
rate of human evolution and one-fifth the 
rate of the fastest evolving python.
In fact, turtles have evolved a distinctive 
Painted turtle DNA holds health clues
S
G E N E T I C S
body design that has changed little over 
the past 210 million years, the authors note. 
Unlike other reptiles, turtles sport a sharp 
beak instead of teeth and live encased in a 
hard shell, a convenient home in which to 
hide when danger lurks.
“Turtles are nothing short of an enigma,” 
says senior author Richard K. Wilson, PhD, 
director of Washington University’s Genome 
Institute. “They may be slowly evolving, but 
turtles have developed an array of enviable 
features. They resist growing old, can repro-
duce even at advanced ages, and their bodies 
can freeze solid, thaw and survive without 
damaging delicate organs and tissues. We 
could learn a lot from them.”
A close look at the turtle genome reveals 
that these creatures do not rely on novel 
genes for their unique physiological adapta-
tions, such as the ability to withstand oxygen 
deprivation. Rather, they activate gene net-
works common to most vertebrates, including 
humans, but use those genes in different 
ways. “This is a back door route for turtles to 
evolve,” says co-author Patrick Minx of The 
Genome Institute. “Rather than evolve new 
genes, they adapted existing genes.”
The scientists identified 19 genes in the 
brain and 23 in the heart that are activated 
in low-oxygen conditions. These genes also 
are present in humans and may be impor-
tant candidates to explore for treatments to 
reduce tissue damage due to oxygen depriva-
tion. They also identified common patterns 
of gene loss in the turtle associated with lon-
gevity, sex determination and a lack of teeth, 



























































In the works    The School of Medicine is  
constructing an energy-efficient, multistory building 
dedicated to interdisciplinary research on some of the 
most complex problems in human biology. Positioned 
along McKinley Avenue just west of Taylor Avenue, 
the facility eventually will house 138,000 square feet 
of highly flexible, open laboratories — spaces that 
can evolve to meet future trends and changing needs. 
Planners broke ground on the $75 million facility this 
summer with a June 2015 target date for completion. 
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Jess and Alice Yawitz, whose relationship with Washington 
University goes back more than 40 years, have established the 
Dr. Phillip and Arleen Korenblat Professorship in the School 
of Medicine. Jess Yawitz, AB ’68, MA ’69, PhD ’72, majored 
in economics and served on the faculty of the Olin Business 
School, where Alice Yawitz earned her MBA degree in 1975.
Supporters of several university schools and programs, the 
Yawitzes’ long association with St. Louis physician Korenblat, 
MD, spurred their decision to endow the professorship.
“I would come home from my physical with Phil, and say, 
‘Phil is so good,’” says Jess Yawitz. “And my wife would say, 
‘He’s the best.’ Aer a while, it was obvious we needed to do 
something to honor him and Arleen.”
An internist in private practice who specializes in allergies 
and asthma, Korenblat has cared for many members of the 
Yawitz family. His own Washington University connection is 
strong: He completed an internal medicine residency in 1965 
and serves as a clinical professor at the School of Medicine.  
He has received many honors, including a Distinguished 
Service Award from the Washington University Medical 
Center Alumni Association. Arleen Korenblat has been  
a benefactor and  
volunteer for many 
organizations. 
While the Yawitzes 
knew Korenblat pri-
marily as a physician, 
Jess Yawitz also knew 
his reputation as an 
outstanding educator. 
“When I would visit 
him, he frequently 
had Washington 
University residents 
trailing him. He 
seemed keen on pass-
ing wisdom down to the next generation,” Yawitz says.
As did Yawitz himself. He joined the Olin School faculty in 
1971 and became the John E. Simon Professor of Finance in 
1981. In 1985 he joined Goldman Sachs in New York, return-
ing to St. Louis in 1988. He currently serves as the chairman 
and chief executive officer of NISA Investment Advisors. 
H. James Wedner, MD, was installed as the Dr. Phillip  
and Arleen Korenblat Professor of Allergy and Immunology 
in Medicine on June 6, 2013. He is chief of the Division of 
Allergy and Immunology in the Department of Medicine, 
and his specialty areas include sinus disease and asthma. 
Couple honors their physician 
and friend with professorship
Elliot L. Elson, PhD, has been elected a fellow of the American 
Academy of Arts and Sciences.
Elson, the Alumni Endowed Professor of Biochemistry 
and Molecular Biophysics, is one of 186 Americans elected  
as fellows this year by the academy, an organization formed 
in 1780 to cultivate the arts and sciences and to recognize 
leadership in scholarship, business, 
the arts and public affairs.
“I am delighted that a member  
of our outstanding faculty has 
received this tremendous honor,” 
says Chancellor Mark S. Wrighton. 
“Dr. Elson is a dedicated scientist,  
and this recognition is well-deserved. 
is achievement demonstrates 
the good fortune we have had at 
Washington University in attracting 
premier faculty.”
Elson also is a professor of  
biomedical engineering in the 
School of Engineering & Applied Science and an adjunct 
professor of physics in Arts & Sciences. His research focuses 
on cellular motion, the movement and distribution of cell 
surface proteins and the forces that determine the shapes  
of cells. He and members of his lab also have studied artifi-
cial cardiovascular tissues, including their mechanical and 
electrical properties.
Elson and his lab members are well-known for designing 
and building unique scientific instruments for highly special-
ized inquiries. One such instrument evolved from a novel 
technique to measure molecular motion.
Elson recognized for research efforts
‘Cancer doesn’t take a Holliday’   St. Louis 
Cardinals left fielder Matt Holliday and his mom, Kathy,  are joining 
forces to spread the word about the importance of colon cancer 
screening. Kathy, who battled the disease last year, says screening 
saves lives.  The two are teaming up with the Alvin J. Siteman Cancer 
Center at Barnes-Jewish Hospital and Washington University School of 










































Arleen and Phillip Korenblat, MD
Clinician and educator is “the best”
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 team of researchers led by 
Washington University School  
of Medicine has identified  
virtually all of the major mutations that 
drive acute myeloid leukemia (AML), a  
fast-growing blood cancer in adults that 
often is difficult to treat. 
The findings, published online in The 
New England Journal of Medicine, pave 
the way for developing better treatments 
for AML based on the genetic profile of a 
patient’s cancer. They also could lead to 
ways to more accurately predict the severity 
of disease in individual patients. 
“We now have a genetic playbook for 
this type of leukemia,” says study co-leader 
Timothy Ley, MD, the Lewis T. and Rosalind 
B. Apple Professor of Oncology in the 
Department of Medicine. “We don’t know 
all the rules yet, but we know all the major 
players. This information can help us begin 
to understand which patients need more 
aggressive treatment right up front and 
which can be treated effectively with stan-
dard chemotherapy.” 
Some 200 patients newly diagnosed 
with AML were involved in the study, 
funded by the National Institutes of Health 
(NIH) as part of The Cancer Genome Atlas 
e trailblazers
A project. Nearly 150 researchers were involved in the effort.A second Cancer Genome Atlas paper 
was published in May in Nature. That 
research, also led by the School of Medicine 
and focusing on endometrial cancer, shows 
that adding genomics-based testing to the 
standard diagnostic workup could change 
the recommended course of treatment for 
some women.
For the leukemia study, the scientists 
sequenced the DNA of each patient’s 
leukemia cells and compared the data to 
DNA from each patient’s healthy cells. They 
found the mutations that only occurred 
in the cancer cells and contributed to the 
development and progression of AML in 
In the footsteps of Lewis and Clark — science team  
forges new exploration in gene mapping
Outlook  7
Like Lewis and Clark’s 
famous expedition of the 
American frontier, the 
new survey of leukemia 
genomes began in St. Louis 
and is an exploration with 
long-lasting influences.
each patient. They also looked for defects  
in RNA (a close chemical cousin of DNA) and 
other changes that alter the expression of 
genes without actually changing the DNA. 
“These results provide important new 
insights into the genomics of a deadly and 
difficult-to-treat cancer, and underscore the 
power and scope of The Cancer Genome 
Atlas project,” says NIH Director Francis S. 
Collins, MD, PhD.
Compared to other adult cancers, AML  
is caused by relatively few mutations. 
Cancer cells in the AML patients had an 
average of 13 mutated genes, far fewer  
than the several hundred typically found  
in breast, lung and other solid tumors.
By studying a large number of AML 
cases, the scientists predict they have found 
nearly all of the major mutations that occur 
in patients with the disease. 
“If only 5 percent of AML cases have a 
particular gene that is mutated, there is a 
greater than 99 percent chance that we 
encountered that mutation at least once in 
this study,” says co-leader Richard K. Wilson, 
PhD, director of Washington University’s 
Genome Institute and research member  
of the Siteman Cancer Center. “There are  
still rare mutations that remain to be  
discovered, but we expect they will fall  
into the same genetic pathways or gene 
sets that we identified as being very 
strongly associated with AML.”
An estimated 14,600 Americans will  
be diagnosed with AML this year and some  
10,400 will die. Unfortunately, few good 
markers exist to help guide treatment  
























Lines in the circos plot 
connect major genes 
involved in acute myeloid 
leukemia with patients 
whose leukemia cells have 
mutations in those genes.














Ed Dodson, MD, begins his 
next chapter having started 
thousands of students in the 
practice of medicine.
B Y  H O L L Y  E D M I S T O N
Outstanding colleague, student mentor, superb physician and educator — these are just some of the ways that colleagues 
describe W. Edwin Dodson, MD, professor of pedi-
atrics and neurology, associate vice chancellor and 
associate dean for admissions and financial aid.
As Ed Dodson retires at the end of 2013, he  
will leave behind a legacy of passion, commitment 
and ethic of duty. Indeed, it’s hard to separate his 
many accomplishments in admissions from his 
remarkable career in pediatric neurology and his 
tireless devotion to community service.
For four decades Dodson has nurtured caring,  
compassionate relationships with his patients and 
their families. For the last 23 years, he also has 
worked passionately to bring the very best students 
to Washington University School of Medicine.
And which aspect of his career will he miss 
most? Dodson replies: “I’ll miss it all.”
In his role as associate dean for admissions, W. Edwin Dodson, MD, center, has nourished relationships with medical school applicants, students and colleagues.
8  Washington University School of Medicine
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experience of the entire class. Medical students spend 
more time with their classmates than they do with any 
other group of people. ey really have a lot of impact 
on each other, and they oen see the world through 
each other’s eyes. A diverse class enriches the experience 
for the students and the faculty.”
why WUSM remains No. 1 in student selectivity
“I think this is a spectacular place. I think incoming 
students come and talk to our current students and 
understand that our students are nurtured, supported 
and encouraged; they recognize that this is a place 
that tries to bring out the best in everybody in our 
community. Students come here and expect that because 
we have such high academic credentials that they’re 
going to see a bunch of competitive, gnarly people, and 
in fact, just the opposite’s true. ey come here and 
see people who are supportive and are helping each 
other. ey come to an environment where everybody 
succeeds; no one has to fail.”
his legacy and retirement
“I hope that I’ve communicated to students that it’s 
OK to do your best, and it’s OK to do something big. 
e practice of medicine is a privilege and it’s a lot of 
fun. e hope is that people who come to medicine 
will be excited by it every day, so they get up and feel 
happy about the activities that lie ahead. When the 
opportunities come along to do something big, I hope 
our students won’t shy away from them.
“I plan to dismiss my patients but look forward to 
continuing to interact with residents and their patients. 
I love fly-fishing, and I want to spend time with my 
great wife, and with friends and my 11 grandchildren  
in beautiful places.”
Seriously, folks!  
Clown arts enhance 








the practice of pediatric neurology
“For me, it’s always been about minimizing the impact  
of the person’s illness or problems so they can pursue 
their dreams. It’s hard to describe how attached  
one becomes to patients and their families. I’ve had 
remarkable continuity with my patients because they 
tend to have neurological disorders that don’t go away;  
I see families that I’ve followed for more than 30 years.  
I feel doubly blessed to be a physician and have such 
rich relationships.”
being dean of admissions
“It’s easy to understand why people dwell so long in  
this position — you interact with spectacular colleagues 
from around the medical school and with students 
throughout their four years or more. And then you  
have the opportunity to get to know some of the 
brightest and best young people in America who are 
applying to medical school. It’s absolutely a gi, and  
just a lot of fun.”
some of the hurdles overcome in admissions
“I do think that the medical school and the medical 
community have addressed the issue of gender imbalance; 
it’s pretty much become a gender-neutral process.
“e issue of maintaining diversity in the class is an 
ongoing challenge. ere’s a short supply of historically 
underrepresented minorities in the applicant pool: 
Mexican-Americans, Puerto Ricans, Native Americans 
and African Americans. Medicine has not been as 
attractive to them as it should be, so the competition for 
underrepresented minority students is very intense.
“ere’s a lot of work taking place on bringing young 
people at the grade school, middle school and high 
school level into the medical community, but they need 
academic enrichment to be prepared for the competitive 
rigors of medical school. So it’s really a pipeline issue, 
an issue of making certain that the people you bring 
into this environment have the skills to succeed.”
current and future challenges in admissions
“Medical school admissions is biased toward people 
from aﬄuent families. ese people have the financial 
resources and come from families who value education. 
ey go to the most selective elementary, middle and 
high schools and then on to the most selective colleges, 
so they come out with a substantial advantage. One of 
the ongoing challenges in medical school admissions is 
to try to get a class that’s also socioeconomically diverse, 
people who have life experiences that broaden the 
Since 1990, W. Edwin Dodson, MD, serving as 
associate dean for admissions and financial aid,  
has led the School of Medicine in recruiting 








No. 1 in student selectivity  
     according to U.S. News & World Report
Highest academic credentials  
     of any class of medical students in the nation
30%     50%  
     increase in the number of female students
5%       15%  
     improvement in minority representation
Ed Dodson on . . . 
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Light already has a major role in medicine — 
specific wavelengths of light are used in various treatments 
and research efforts — but that role may be growing.
X-rays, which are invisible to the eye, can make the stuff 
inside us visible. Ultraviolet light can treat skin diseases  
such as psoriasis. And bright light boxes help stabilize  
the moods of patients with seasonal affective disorder.
Beyond these applications, investigators at the School  
of Medicine’s Department of Anesthesiology are using 
genetic engineering to influence how cells respond to light.
One team is investigating proteins in the eye called 
opsins, which allow photoreceptor cells to convert light into 
vision and enable us to see, to activate other types of cells. 
This allows the scientists to use light to control cell behavior.
Other investigators are working with optogenetics — 
using light to influence specific neurons in animals in order  
to map brain circuits and understand complex behaviors 
related to sleep, depression, anxiety and pain.
Potentially their findings could allow the development  
of precisely targeted light-based therapies.
C E L L STaking a shine to
B Y  J I M  D R Y D E N
Lighting the way to understanding the workings of cells,  
network activities and possible future therapies 
10  Washington University School of Medicine
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C E L L S
Ajith Karunarathne, PhD, 
activates opsin-expressing cells 
with a selected wavelength of 
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Moving single cells
You can see this page because your eyes have opsins — light-sensitive receptors in cell membranes — responding to varying 
light. Those subtle, natural responses suggest 
a daring idea: What if other body cells were 
modified to respond to light? Immune cells could 
speed toward a lighted wound; light pulses could 
regulate a heartbeat. This experimental concept 
is more useful than a simple on/off toggle; 
think of it more like a dimmer switch that can 
control the intensity of the response. Exploring 
various creatures’ opsins — from pufferfish to 
mosquitoes — will provide additional insights.
With light-sensitive opsins added to its
membrane, this immune cell responds
to the light and moves toward it as





































Opsins can do more than “see” in the way we typically 
think of seeing. In fact, they can activate cells to respond  
to their environments.
N. Gautam, PhD, professor of anesthesiology and genetics, 
and postdoctoral research associate Ajith Karunarathne, PhD, 
are exploring how light can cause opsins to behave in cells. 
When they inserted opsin proteins, which are G protein-
coupled receptors (GPCRs), into cells, they found that by 
shining light on the cells, they could activate specific areas. 
is bit of genetic engineering permits opsins to activate 
other types of cells.
 “Some of these opsins have properties that we thought 
might allow us to localize the signaling activity in a cell to a 
particular location in the cell,” says Gautam. “So we began 
experimenting, and we found that we could, in fact, localize 
the signaling to one side of the cell or another. A great deal 
of cell behavior results from signaling where the cell will 
sense something on its right, for example, and then move 
toward that substance, or move away from it.”
An immune cell, for instance, that receives a signal and 
senses a bacterial infection or inflammation, will travel in 
the direction of the bacteria or the inflammatory molecules. 
When Gautam and Karunarathne inserted opsins into 
immune cells, the cells moved towards a light beam.
“We can use light as a kind of ‘on-off’ switch to control 
cell behavior,” says Gautam. “Much of the way cells behave is 
due to their ability to sense signals in the environment.  
In our experiments, the cells sense the presence of light.”
In neurons, they have used light to coax the cells into 
growing new branches called neurites. ey are planning 
similar things in heart cells and in pancreatic cells. 
e goal with the heart cells would be to use light to  
slow down, or speed up, the rate at which the cells pulse.  
In pancreatic cells, they want to use light to get the cells  
to secrete insulin. 
“We believe that with these techniques, it’s likely that  
any process that can be controlled by signaling from GPCRs 
can also be controlled by light,” Gautam says.
Although Gautam believes that inserting opsins into cells 
has immense therapeutic potential, he says it will be a while 
before the strategy is ready for clinical use. For one thing, 
it will require gene therapy in order to introduce the light-
sensitive proteins into specific cell populations. For another, 
it will require a way to introduce light into cells deep inside 
the body, perhaps using micro-light emitting devices (LEDs). 
While his laboratory is working on ideas to take this 
strategy from the culture dish into whole animals, they  
also are creating a library of several different opsin proteins 
capable of controlling cell behavior.
 “As we move forward, one of our goals is to continue 
testing multiple opsins from different organisms to learn 
which ones work best,” he says.
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Activating cells in a network
Light can influence neurons in animals that have been 
genetically engineered so that specific neurons will be acti-
vated and respond to light. Michael R. Bruchas, PhD, assis-
tant professor of anesthesiology, and Robert W. Gereau IV, 
PhD, professor of anesthesiology and of neurobiology, are 
part of a group of scientists working in optogenetics.
rough their work with collaborator John A. Rogers, 
PhD, and engineers at the University of Illinois, they 
received a $3.9 million Transformative Research Project 
award supported by the National Institutes of Health (NIH). 
e researchers developed microscale, light-emitting 
devices (LEDs) — the first use of these devices in optogenet-
ics — that allow them to map the properties of neural cir-
cuits involved in injury, pain, anxiety and other problems. 
Bruchas was able to implant the devices in mice, prodding 
their neurons to release dopamine, a chemical associated 
with pleasure. Because the LEDs are wireless and tiny, they 
don’t interfere with normal behaviors. e mice move freely 
about their cages and can explore a maze or run on a wheel.
Bruchas and the investigators taught the mice to poke 
their noses through a specific hole in a maze. Each time, the 
system wirelessly activated the micro-LEDs, which emitted 
light, causing neurons to release dopamine.
“e micro-LEDs activated networks’ cells that are influ-
enced by the things humans also find rewarding, like sex 
or chocolate,” says Bruchas. “When the cells were activated 
to release dopamine, the mice quickly learned to poke their 
noses through the hole even though they didn’t receive food 
as a reward.”
He says the devices should allow scientists to identify  
and map brain circuits involved in many complex behaviors. 
“Understanding which populations of neurons are involved 
in these complex behaviors may allow us to target specific 
brain cells that malfunction in depression, pain, addiction 
and other disorders,” Bruchas says.
In Gereau’s laboratory, the devices are implanted near 
peripheral nerves to interrupt or redirect pain signals. 
“Rather than identifying specific stimuli, we just want to 
turn off the cells causing pain,” says Gereau, who is director  
of the Washington University Pain Center. 
But before those devices will relieve pain or stress, 
patients will need gene therapy that makes certain cells 
respond to light signals.
Gereau believes a common-sense strategy for doing so  
lies in a viral attack on the peripheral nervous system. 
 “If we can find a way to use a harmless version of the 
herpes simplex virus to deliver light-sensitive proteins to 
peripheral nerve cells, we believe we may be able to control 
the activity and signaling of those cells,” says Gereau.
 Bruchas, Gereau and colleagues hope that someday their 
work with micro-LEDs may illuminate ways of controlling 
behavioral disorders and pain in humans.
Depression, pain, stress, addiction — which cells play a part? Micro-scale  lights (smaller than the eye of a needle) 
can help illuminate these vexing questions.  
For example, in the mammalian brain at right,  
only genetically modified, light-sensitive neurons 
are activated, resulting in modified behaviors. 
There may be a way — perhaps via a harmless 
virus — to deliver light-sensitive proteins to 
human nerve cells. These bright ideas could 
someday alleviate pain, modify mental disorders 
and otherwise improve the human condition. 
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B Y  J U D Y  H .  W A T T S
when ultrasound screenings in pregnancy indicate that babies’ tiny systems may be developing irregularly, or family medical 
histories suggest anomalies may occur, doctors from 
around the region refer mothers to the Fetal Care Center 
(FCC). With their hopes badly shaken for an uneventful 
pregnancy and a healthy baby, families arrive at the center 
longing for answers, for interventions from medical science, 
for hope. And they nd these things, in their many forms, 
as they are guided through a compassionate sequence of 
physical and emotional care. 
FCC medical co-director and neonatologist Barbara 
B. Warner, MD, MSCE, specialized in newborn medicine 
because she was drawn to working with ill and premature 
newborns and their families. “Helping and supporting  
is a great privilege,” says Warner, professor of pediatrics  
in the Department of Pediatrics, whose neonatal group  
is ranked among the top three in the United States, 
according to U.S. News & World Report. 
Adds medical co-director and medical geneticist  
Lisa M. Bernhard, MD, “With our comprehensive, in-depth 
care, we give babies their very best possible chance. We 
do all we can to make these terribly stressful months in 
families’ lives as easy and as seamless as possible.” 
the long way
homeDelivering exceptional care when expectant families face the unexpected
One to grow on: Dillon, who 
was treated for congenital 
pulmonary airway malfor-
mation, with his mom, Carol 
Waeckerle, and Fetal Care 
Center co-directors Barbara 
B. Warner, MD, MSCE, left, 
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Although every major medical center has some type of 
coordinated fetal care, center founder and director George 
A. Macones, MD, MSCE, explains the goal of the Fetal Care 
Center, which is a joint effort of Washington University 
School of Medicine, Barnes-Jewish Hospital and St. Louis 
Children’s Hospital.  
“We are fully focused on our patients — mother and baby 
— and the family. We bring very upset parents into the Fetal 
Care Center, which is part of a complex quaternary medical 
center made up of world-class physicians and hospitals, but 
we make sure they get lots of information and know we’re 
taking complete care of them through this difficult time,” 
says Macones, the Mitchell and Elaine Yanow Professor, head 
of the Department of Obstetrics and Gynecology, and that 
department’s director of maternal–fetal medicine and ultra-
sound. “at special care isn’t just during the initial evalua-
tion: It extends through pregnancy, delivery and aerward.” 
Macones is internationally known as a clinician and perinatal 
clinical researcher. 
Overseeing all the personal attention patients receive is 
a nurse coordinator at the FCC or, if a cardiac problem is 
involved, from the Fetal Heart Center, part of the St. Louis 
Children’s and Washington University Heart Center. Nurse 
coordinators like Christine Hoover, BSN, RN, are a resource 
and partner throughout the journey to delivery. “We’re with 
families from the time they arrive until we walk them to 
their car,” she says. Nurse coordinators accompany mothers 
to all tests, meetings and consultations, “making sure every-
one is on the same page and answering families’ questions.
“We also tour the facilities to help parents feel comfort-
able,” Hoover continues. “If we see it’s too much, we stop.” 
Recently a mother told Hoover, “Yes, I really want to see the 
NICU.” But when they entered the hushed, darkened room, 
where sick infants slept next to sophisticated instrumenta-
tion and some parents sat crying, she burst into tears. 
“We postponed the rest,” Hoover says. “We always act  
on the patient’s wishes, including rescheduling appointments 
and obtaining temporary physician privileges at Barnes-
Jewish if a patient wants her own obstetrician to deliver her 
baby. As many as 12 extended family members have attended 
consultations! We do everything we possibly can to make 
things better.”
Diagnosing a fetal anomaly that confirms or modifies a 
referring physician’s finding — or discovering that the fetus 
is normal — is the work of the ultrasound and genetics side 
of maternal–fetal medicine. “When we find an abnormality, 
we look very carefully for other problems, because very oen 
when one exists, other conditions are present that may not 
have been identified,” says Bernhard, assistant professor of 
obstetrics in the Department of Obstetrics and Gynecology’s 
Division of Maternal–Fetal Medicine (MFM). “en we 
discuss what, with patient consent, should be done — such 
as amniocentesis or a fetal MRI — to try to discover why a 
particular birth defect has occurred.” Following the com-
prehensive assessment, “We go in right away to talk with the 
parents, and then we contact the referring physician.”
Jacqueline Turner, MD, of West End Ob/Gyn, in St. Louis, 
sends all her pregnant patients to the ultrasound and genetics 
group for their early, routine ultrasound. “We prefer that 
those physicians do the screening,” she says, “because if 
there’s an issue, we know they’ll find it. If something major  
is wrong, they actually call me at the time they’re doing the 
ultrasound.” For families and referring doctors alike, she 
adds, the FCC is a “great service.”
Leading the ultrasound and genetics team is maternal–
fetal medicine specialist Anthony A. Odibo, MD, MSCE, 
whose ultrasound and fetal-abnormality research is known 
worldwide. Odibo is also skilled in treating Twin-Twin 
Transfusion Syndrome (TTTS), which can affect identical 
twins who share a single placenta. In this condition, one twin 
transfuses blood to the other, producing anemia and drasti-
cally slowed growth in the donor and excessive growth and 
blood volume in the recipient. 
He and his colleagues also use endoscopic surgery to place 
shunts in tiny obstructed bladders, and they correct amniotic 
band syndrome, wherein a strand of the amniotic sac mem-
brane has wrapped itself so tightly around the baby that loss 
of digits or blocked placental blood delivery can occur. 
Caroline K. Lee, MD, 
consults with  
mother Misty  
Nutter and baby 
Austin Rakers.
Personal touch: Nurse coordinator Christine Hoover, left, walks mom Theresa 
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“We provide evidence-based, safe care,” says Odibo, pro-
fessor of obstetrics and gynecology and vice chair for women 
and fetal imaging. “Before we use new procedures in which 
some risk may be involved, the situation must be one in 
which we know definite evidence exists that prenatal surgery 
or intervention is better than doing nothing. at’s where we 
differ from some of our competitors.”
Fetal cardiac problems account for about 50 percent of 
anomalies seen at the Fetal Care Center. In all cases, once 
the MFM specialists have examined the heart and the whole 
baby, fetal cardiac nurse coordinator Kym Galbraith, BSN, 
RN, accompanies mother and family to the adjacent Fetal 
Heart Center. ere, pediatric cardiologists use echocardiog-
raphy in a 30- to 60-minute noninvasive test to check cardiac 
function and structure. 
“Our heart center is completely full-service,” says 
Caroline K. Lee, MD, assistant professor of pediatrics, 
associate director of the Pediatric Cardiology Fellowship 
Program and director of fetal cardiology. “Every heart  
specialty is represented.”
e professional roster at Children’s, a leading transplant 
center, includes three electrophysiologists, not found at many 
centers, three cardiac catheterization physicians and 50 spe-
cialists who can administer extracorporeal membrane oxy-
genation (ECMO), an advanced treatment that does the work 
of heart and lungs. e hospital’s pediatric subspecialists 
represent every existing category, ready to step in as needed 
before and aer delivery, and newborn neurology provides 
neurological imaging, monitoring and consultation. 
When a sick infant is born at Barnes-Jewish Hospital, with 
every necessary expert in attendance, the child is stabilized 
and placed in a life-supporting isolette. A specialist takes the 
newborn and father to the Newborn Intensive Care Unit 
(NICU), where a neonatology nurse coordinator waits.  
e mother and an attendant visit shortly aerward. Seeing 
their infant for the first time marks the start of a second, 
hopeful journey for many parents, who have already learned 
about planned treatments or surgeries. 
But about 20 percent of FCC families, says Warner,  
“have infants with lethal disorders. And while we may not 
be able to reverse that process, we provide the baby with 
warmth, pain medication — whatever he or she needs to  
be comfortable. And if a baby will die, we can still provide 
the family with a meaningful experience with their child 
that they’ll always cherish.”
Regardless of the prognosis, Joan L. Rosenbaum, MD, 
director of palliative care and professor of pediatrics, is  
central to providing comfort and support. Rosenbaum  
gets to know the families personally in the months  
before birth and helps them identify their wishes. Among  
these may be spiritual requests, such as wanting their  
infant baptized.
“Joanie writes a beautiful letter detailing the parents’ 
wishes, so that they are communicated to everyone involved 
in their infant’s care,” says Hoover, the nurse coordinator. 
“Just last week, a family from southern Missouri met with 
her. e first hospital they visited wouldn’t allow them to 
have a photographer and other simple things that would 
mean everything to them. ey decided to come here for 
care because they felt, in the mom’s words, that we honored 
her and her baby and valued them both.”
As the FCC looks to the future, one goal is overarching. 
And that, as Lisa Bernhard puts it, is further refining and 
focusing on the patient experience.
“Our physicians and staff care so much more than our 
patient families even realize,” says Christine Hoover.
Ultrasound diagnostics
Anthony A. Odibo, MD, MSCE, professor of 
obstetrics and gynecology and an inter-
national leader in ultrasound and fetal 
abnormality research, leads the Fetal Care 
Center’s ultrasound and genetics group. 
Ultrasound is one of a range of diagnostic 
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CARE
The promise of a healthy pregnancy 
sometimes changes in a heartbeat.  
The Fetal Care Center (FCC) helps  
these mothers and families walk  
their more challenging paths, offering  




A routine checkup near the end of the first trimester 
indicates a possible anomaly in the pregnancy.  
The woman’s physician refers her to the FCC for 
further evaluation.
All things considered
A nurse coordinator welcomes the family and 
escorts them through the diagnostic sessions. 
Single problems can signal multiple issues;  
tests range from imaging to genetics and more. 
Family matters
The FCC responds with sensitivity and respect to 
families’ needs during these difficult, stressful days. 
The prognosis is carefully considered and support 
provided for making choices and moving forward.
C O N T I N U U M 
 o f
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Go, Team
Hayden!
Hayden Hoskins is just one  
of the many infants cared  
for at the Fetal Care Center. 
Ultrasound revealed Hayden’s 
omphalocele; his organs were growing 
outside his belly. Parents Andy and  
Kelsea were referred to the FCC. After Hayden was 
delivered at Barnes-Jewish Hospital, he was rushed 
to the NICU at St. Louis Children’s Hospital. Five 
months later, a surgical team placed his organs 
internally. Today, Hayden has a lot to smile about.
The journey continues
In utero interventions may be essential for further 
diagnoses or to stabilize the pregnancy. The care 
team coordinates an evidence-based medical plan 
that maximizes health benefits and minimizes risks. 
The big day arrives
A team of specialists stands ready to deliver skilled 
care before, during and after delivery. Every baby 
has a spectrum of special needs; the team works to 
meet those needs and honor the family’s wishes.
Newborn and beyond
Very sick infants receive optimal care during their 
too-short lives. Many more babies will benefit from 
specialty procedures during the months ahead, 
helping ensure lifetimes of happy birthdays. 
HAYDEN’S TEAM:  Christine Hoover, BSN, RN, nurse coordinator;  
Brittany Knipstein, MD, fellow, neonatology; Brad W. Warner, MD,  
the Jessie L. Ternberg, MD, PhD, Distinguished Professor of  
Pediatric Surgery and surgeon-in-chief, St. Louis Children’s Hospital;  
baby Hayden Hoskins; parents Andy and Kelsea Hoskins;  
Alison G. Cahill, MD, MSCI, assistant professor of obstetrics and  








133484_fetal_14-19_CS6.indd  19 8/28/13  5:30 PM




C HOIC E S
Stereotactic  
body radiation  
therapy
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Week after week, newly diagnosed patients with early-stage lung cancer — mostly men in their mid-60s who are longtime smokers — come to Washington 
University physicians, seeking a successful form of treatment. If 
they are otherwise healthy, thoracic surgeons Traves D. Crabtree, 
MD, and Varun Puri, MD, perform minimally invasive surgery 
to remove the lesion; if they have complicating conditions that 
preclude surgery, radiation oncologist Jeffrey D. Bradley, MD, relies 
on stereotactic body radiation therapy (SBRT). But for patients in 
the gray area between the two extremes, which treatment is best?
For several years, these physicians and surgeons have been 
trying to resolve this question by mining local and national 
databases of past patients for answers. Further, they have been 
working collaboratively, without the competition often seen at 
other institutions. Together, they are not only trying to determine 
which therapy to use in which cases, but more broadly what 










coronary artery disease or respiratory problems? Which factors 
really matter in determining a patient’s ability to survive surgery 
and return to the best possible stamina and function?
“The colleagues we have aligned in thoracic surgery and 
radiation oncology are unique,” says Bryan F. Meyers, MD, MPH, 
chief of thoracic surgery and the Patrick and Joy Williamson 
Professor of Surgery. “We scrutinize each other’s patient data 
together, we go over each analysis together and we have no 
shyness about challenging the other’s work. Our papers have 
truly been joint efforts and represent our best effort to inform the 
patients about the most likely outcomes from either modality.”
The result has been national prominence in this area for  
Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and 
Washington University School of Medicine. “Only a handful of 
other institutions have looked at this problem in as much detail  
as we have,” says Crabtree, assistant professor of surgery, who  
was the first author on a 2010 study comparing groups of patients 
treated with both therapies and tracking long-term outcomes. 
C HOIC E S Deciding between two cancer therapies
Traves D. Crabtree, MD,  
right, and Varun Puri, MD, 
center, work with a surgical 
team to remove a tumor.
Jeffrey D. Bradley, MD, right,  
confers with dosimetrist Michael B. 
Watts regarding a patient’s  
SBRT treatments.
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Before they adopted SBRT as 
a treatment option in 2004, 
their results from the previ-
ous method — daily radiation for 35 treatments —were “just 
lousy,” says Bradley, the S. Lee Kling Professor of Radiation 
Oncology. Intrigued by reports of SBRT, he traveled to 
Germany and Japan to learn the technique, and he and his 
colleagues became national leaders in adopting it. ey have 
since treated some 500 patients, and the outcome “has been 
excellent,” he adds. “Our primary tumor control rate is  
better than 90 percent, and we’re thrilled with the results.”
SBRT works so well because it is a precisely targeted treat-
ment in which radiation beams are arrayed around a tumor, 
and the maximum dose is focused directly on the cancer, 
minimizing the exposure of adjacent tissue. Specialized 
equipment is necessary for the therapy: body-positioning 
apparatus to keep the patient immobile for the 30-minute 
session, and a linear accelerator with multi-slice CT imaging 
that shows even slight tumor movement. Over a week’s time, 
a patient has three to five treatments and then is done, with 
little post-operative discomfort.
Bradley’s early advocacy for SBRT drew the attention  
of thoracic surgeons, and his team began collaborating with 
them on widely published multidisciplinary research. 
Recently, Clifford Robinson, MD, assistant professor  
of radiation oncology, became chief of the SBRT service.  
e service has grown under Robinson’s leadership, and he 
undertook surgery/SBRT analyses with Crabtree and Puri. 
“Without Cliff’s work, we would not have been able to 
accomplish these studies,” says Crabtree.
Removing the lobe of the 
lung containing the cancer 
has long been the recom-
mended treatment for early-stage non-small cell lung cancer, 
a biologically aggressive disease with a five-year survival of 
60 to 75 percent. In recent years, cancer surgery has become 
safer, with a surgical mortality rate of just 1 percent; recov-
ery is also much easier because of the increasing dominance 
of minimally invasive techniques. More than 75 percent of 
lung cancer surgery at Barnes-Jewish Hospital is now done 
using this approach.
“Large-incision patients will feel much worse than those 
who have had three small incisions and cancer removal. 
Small-incision patients go home sooner, feel better, are 
less likely to need pain medications and are more likely to 
be independent,” says Puri, assistant professor of surgery. 
“Long-term, oncologically, this surgery provides equal  
benefit to the big operation.”
ese minimally invasive techniques mean thoracic sur-
geons are more likely to offer surgery to a patient with com-
plicating conditions because they can do the operation more 
safely than they could have a decade ago. us, the gray area 
of patients who may or may not be candidates for surgery 




For those patients who fall 
within the puzzling gray 
zone, further research 
is needed. Aer Crabtree’s 2010 paper in e Journal of 
oracic and Cardiovascular Surgery, Puri — who has 
received support from an NIH Career Development Award 
and from the Foundation of Barnes-Jewish Hospital — was 
principal author of an analytic modeling paper that looked 
at cost-effectiveness for both options. ese studies, based on 
retrospective data, showed that surgery was somewhat more 
expensive than SBRT but resulted in better overall survival. 
In the gray-area patients, cancer-specific survival was similar 
between SBRT and surgery.
For even more conclusive results, the best solution would 
be to mount a prospective trial, randomizing new patients to 
SBRT or surgery — but that has proved difficult. ree mul-
ticenter national trials have failed to accrue enough patients; 
the last one, with Bradley as a principal investigator, closed 
in May 2013. In large part, the reason is that patients have 
strong opinions about the form of treatment they want.
“On one end of the spectrum, patients say: ‘I want this  
out of me. Let me have surgery.’ On the other end, they say: 
‘I am 75 years old, and you think I want to have a big sur-
gery? If SBRT doesn’t work, I can have surgery aerward.’ 
It is hard to randomize patients because you’re taking the 
choice away from them,” says Bradley. 
Right now, he and his colleagues continue to plan new 
studies. oracic surgeon Stephen Broderick, MD, is col-
lecting data on the quality of life of lung cancer patients 
treated either with surgery or with SBRT. In the short term, 
Crabtree, Puri and Robinson hope to develop one computer-
based algorithm for SBRT patients and another for surgery 
patients, so that physicians will be able to describe their 
chances of long-term survival with each method.
These studies will better inform  


























   Care to 
TA NGO ?
B Y  J U D Y  M
A R T I N  F I N
C H
Paradoxically, complex dance  
moves could benefit patients  
with movement disorders:  
Gammon Earhart, PhD,   
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                             It is fitting that Gammon Earhart 
began her research career working with a device 
that resembles a giant turntable. Music — tango 
music in particular — has become an important 
component of her work with Parkinson’s disease. 
Earhart, PT, PhD, associate professor of physi-
cal therapy, neurology and neurobiology, used a 
rotating treadmill for studies on healthy people 
while she was a postdoctoral researcher at Oregon 
Health & Science University. Her research dem-
onstrated that when people walk on a rotating 
surface for a period of time, then step off, they 
are unable to walk in a straight line. e process 
forces them to turn. 
She took her research to Washington University 
School of Medicine when she joined the faculty 
of the Program in Physical erapy in July 2004. 
She began working with people with Parkinson’s 
disease, a chronic and progressive movement 
disorder that involves the malfunction and death 
of neurons. As the disease progresses, people are 
unable to control movement normally. 
“Turning is something that people with 
Parkinson’s disease are particularly troubled by,” 
says Earhart, a member of the Movement Disorder 
Center in neurology. “ey try to make a turn but 
get stuck and feel like their feet are glued to the 
floor. at can lead to falls and the consequences 
related to falls.” 
One of her key goals is to help them make 
turns. “It was that interest in turning behavior 
— in healthy people and in Parkinson’s patients — 
that eventually led me to the dance floor,” she says. 
In 2005, Earhart attended a Society for 
Neuroscience meeting and saw Canadian 
researchers present an abstract focused on frail, 
elderly individuals randomly assigned either to 
walk in a group for exercise or learn to dance the 
tango. e researchers’ findings indicated that 
those assigned to dance had improved their bal-
ance more than those assigned to walk.
When Madeleine Hackney, PhD ’09, a profes-
sional dancer turned graduate student, began 
working in Earhart’s lab, it gave Earhart an idea.
“I thought, ‘Madeleine can certainly do the 
tango.’ And aer talking to her, Madeleine agreed 
that we should try a pilot study incorporating the 
dance for people with Parkinson’s,” she recalls.
It proved difficult to recruit patients at first. 
Many thought they couldn’t dance — espe-
cially the tango — with a disease as limiting as 
Parkinson’s. But eventually enough patients were 
recruited, and the pilot study went well. 
“e participants were pleasantly surprised at 
how much they could still do, and they enjoyed it,” 
Earhart says. “And our outcome measures showed 
that, when compared with a group of people who 
had taken a traditional exercise class, there were 
more significant improvements regarding balance 
and walking in the people in the tango group.” 
Encouraged and excited by the results, Earhart 
and Hackney moved forward with their research. 
Subsequent studies have included 10 days of 
classes over two weeks, which the researchers refer 
to as “Tango Boot Camp,” to a study that offered 
classes twice a week for a full year. e most typi-
cal design, however, offers classes twice a week for 
three months. 
eir findings have shown that tango-dancing 
patients experience improvements that are as good 
as or better than those who exercise using other 
forms of dance, such as the waltz or fox-trot, or 
alternative approaches, such as T’ai Chi.
Earhart theorizes that tango’s benefits come 
from incorporating specific movements that peo-
ple with Parkinson’s oen have difficulty perform-
ing, such as walking backward. 
  
The most important finding has come from the 
year-long study. Participants were evaluated before 
they started dancing and then again aer three 
months, six months and 12 months. is group 
was compared with another group of people who 
had Parkinson’s but were not exercising over the 
same time period. 
“We noted that at three months and then again 
at six and then 12 months, the people who were 
participating in tango dancing were improving 
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for people with a neurodegenerative disease like 
Parkinson’s,” Earhart says. “at suggested we 
were potentially modifying the trajectory of the 
disease’s progression with participation in the 
tango exercise program. at could have very 
positive ramifications.” 
Earhart noted other improvements in the 
study participants’ lives, as well. Some picked up 
activities they previously had given up, and some 
engaged in new social activities. Increased activity 
did not occur in the non-dancing group.
Susan Deusinger, PT, PhD, FAPTA, director of 
the Program in Physical erapy, says that Earhart 
“has emerged as a leader in understanding the 
neurological foundation of movement and how 
degenerative diseases of the brain affect move-
ment, health and function in daily life. While 
her work is especially important for patients with 
Parkinson’s disease, it also represents a line of 
inquiry that blends basic and applied themes in 
creative and innovative ways.” 
In a new study, supported by a recent $1.5 million 
grant from the National Institute of Neurological 
Disorders and Stroke, Earhart will compare tango 
dancing to walking on a treadmill. She plans to 
control for social factors as much as possible by 
arranging the treadmills in clusters so participants 
can talk to one another, as dance partners do. 
In addition to evaluating each participant’s gait, 
balance, cognitive function, severity of disease and 
quality of life, Earhart will utilize neuroimaging 
with functional MRI (fMRI) as part of the study.
Joel Perlmutter, MD, professor of neurology, 
radiology, neurobiology, physical therapy and 
occupational therapy, has a database that includes 
more than 2,400 Parkinson’s patients, some of 
whom may be potential candidates for Earhart’s 
study, which calls for 120 participants. 
“We hope to determine whether brain activity 
or brain connections change as a result of partici-
pating in the exercise programs, and whether the 
changes that result from tango dancing are the 
same as or different from the changes that result 
from using a treadmill,” Earhart says. “We want to 
determine whether the changes we see in the brain 
are related to changes in physical performance.” 
Earhart says her research would be more dif-
ficult, if not impossible, if she were somewhere 
other than the School of Medicine. “ere’s no 
way we could involve so many participants with-
out the resources provided through the Movement 
Disorder Center and the Greater St. Louis 
American Parkinson Disease Association.” 
“We found that the people who were tango 
dancing were improving instead of deteriorating, 
which is unexpected for people with a 
neurodegenerative disease like Parkinson’s.” 
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If you wish to make a tribute gift in honor 
of any of the above alumni or faculty, 
please contact: Pamela Buell, Washington 
University Medical Alumni and Development, 
Campus Box 1247, 7425 Forsyth Blvd., Suite 2100, 
St. Louis MO 63105-2161, (314) 935-9691.
classnotes
1940 S 
Llewellyn Sale, MD 40
Sale, a resident of St. Louis MO, contin- 
ued to work part-time until June 2011.  
In retirement, he enjoys reading, mild  
exercise and Wii bowling.
Barber Mueller, MD 42
Mueller is retired and resides in Ontario, 
Canada. He completed the final para-
graphs of Excalibur, The Sword of Science 
that Shaped the World, a book he had been 
working on for the past eight to 10 years. 
It brings an overview of ideas generated 
during the Age of Science that have  
forever changed our perception of the  
universe and of man’s place on Earth.
John Wilson, MD 43
Wilson and his wife, Helen, recently  
celebrated their 69th wedding anniver-
sary. One of his fondest memories from 
medical school is meeting Helen, a  
Barnes Hospital dietitian, in the cafeteria.
1950 S 
Rudenz Douthat, MD 54
Douthat is retired and living in 
Fredericksburg TX. He has been honored 
by the American College of Emergency 
Physicians (ACEP). He looks forward to 
reuniting and celebrating with fellow  
1954 classmates at Reunion 2014.
Robert Winter, MD 58
Winter was honored by the Scoliosis 
Research Society in 2012 with its Lifetime 
Achievement Award and the founding 
of the Robert B. Winter Global Outreach 
Education Fund.
1960 S 
Melvin Dace, MD 62
Dace recently retired as Chief of Stadium 
Medical Operations for the University of 
Florida football team — the Florida  
Gators — after having held the position 
for 17 years. He also served as assistant 
medical director of the 1996 Olympics in 
Atlanta GA and for 25 years as a cardiolo-
gist in private practice.
John Crane, MD 64
Crane works two days a week at a mental 
health clinic. He looks forward to celebrat-
ing his 50th wedding anniversary next 
year with his wife, their three sons and 
seven grandchildren. Crane and his wife 
travel often in their small motor home 
with yellow lab, Lily Pearl. He also enjoys 
sailing with his sons at Carlyle Lake.
Doris Abrams, NU 67
Abrams retired after 43 years of practice in 
various areas of pediatric nursing (neona-
tal ICU, med/surg, rehab, school nursing, 
home care) and is now enjoying garden-
ing, travel, reading, movies, theater and 
maintaining “kid-kontact” at a local early 
childhood center.
1970 S 
Bruce Fisher, MD 70
After retiring from full-time work in 2011, 
Fisher has been teaching at Jersey Shore 
University Medical Center focusing on 
clinical reasoning and basic bedside skills.  
In 2012, he co-authored the 3rd edition  
of Lippincott’s Illustrated Reviews: 
Microbiology.
Marshall Bloom, MD 71
Bloom maintains an active career at the 
National Institutes of Health as both chief 
of the Tick-Borne Flavivirus Section and as 
associate director for scientific manage-
ment at Rocky Mountain Laboratories in 
Montana. In 2011–12, he was chairman of 
the organizing committee for the American 
Society for Microbiology Biodefense and 
Emerging Diseases Conference, and he was 
elected a Fellow of the American Academy 
of Microbiology in 2013.
Charles Ettelson, MD 78
Ettelson has retired from clinical practice 
and started a second phase of his career 
as a medical director at UnitedHealthcare, 
St. Louis. He recently appeared as a con-
testant on “Jeopardy,” and his performance 
is viewable on YouTube.
1980 S 
Chris Pool, HA 83
Pool is with UnitedHealthcare Military 
& Veterans Services as chief executive 
officer for the Northwest region. He is 
responsible for TRICARE field operations 
for Washington, Oregon, Idaho, Montana, 
Alaska and Northern California.
Margaret Steinhoff, MD 83
Steinhoff is director of surgical pathol- 
ogy and chair of the cancer committee  
at Women and Infants Hospital of  
Rhode Island.
1990 S 
Joan Blomquist, MD 92
Blomquist is chief of the Division of 
Urogynecology and Reconstructive Pelvic 
Surgery at Greater Baltimore Medical 
Center. Additionally, she travels annually 
with the International Organization for 
Women and Development to Niger and 
Rwanda to perform and teach fistula  
surgery.
Jane Chen, MD 93
Chen is an associate professor of medicine 
in cardiology at Washington University 
School of Medicine. She focuses her 
practice on patients with diagnosed or 
suspected heart rhythm abnormalities, 
pacemakers or defibrillators and was rec-
ognized as a “Best Doctor” in 2011 by  
St. Louis Magazine. She enjoys spend-
ing time with family (sons Marcus and 
Harrison), reading and playing the piano.
Marc Seidman, MD 98
Seidman is a pediatrician living in  
Fort Collins CO. He and his wife have  
two daughters, Gabi and Anna.  
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2000 S
Jared Hershenson, MD 04
After completing a pediatric cardiology  
fellowship at Nationwide Children’s 
Hospital in Columbus OH, Hershenson is 
now working in the greater Washington 
DC area with Child Cardiology Associates.  
Andrew Zimolzak, MD 07
Zimolzak completed an internal medicine 
residency and chief resident year at Saint 
Louis University. He is now enrolled in a 
master’s program in medical informatics at 
Harvard Medical School. He and Elizabeth 
Moulton, GM 11, MD 11, are engaged.
Michelle Moniz, MD 08
Moniz has been selected as a 2013  
Robert Wood Johnson Foundation  
Clinical Scholar. She will conduct innova-
tive research and work with communities,  
organizations, practitioners and policy-
makers to take a leadership role in 
improving health and health care in the 
United States. Her fellowship begins at the 
University of Michigan in fall 2013.
I M 
Jane Arax Erganian, BA 37, MD 41
Erganian died on March 3, 2013. She was 
96. She pursued a specialty in pediatrics. 
While a resident at New York Hospital, 
she met her husband, Armig G. Kandoian.  
With him she raised three daughters and 
eventually returned to her profession, 
enjoying many years as Senior Public 
Health Physician for the New Jersey State 
Department of Health.
Vergil Slee, MD 41, MPH
Slee died at age 94 on July 31, 2012.  
After completing a medical internship at 
Barnes Hospital, he became a flight sur-
geon for the U.S. Air Force, then earned an 
MPH from the University of Michigan. He 
founded the Professional Activity Study 
(PAS), the prototype of computerized  
hospital discharge systems used today.
John Farrar, MD 45
Farrar died on June 26, 2012, at age 92. 
After serving in the U.S. Army Medical 
Corps, he trained in gastroenterology. 
He taught at Boston University School of 
Medicine and Cornell University College 
of Medicine before becoming the chair 
of the Division of Gastroenterology at 
the Medical College of Virginia (now VCU 
Medical Center). He served in several posi-
tions for the U.S. Department of Veterans 
Affairs. After retiring, he remained active 
in medicine and in his community.
Henry Hosford, MD 51
Hosford died on June 13, 2012. A World 
War II U.S. Army veteran and New Mexico 
native, he moved to St. Louis to attend 
Washington University School of Medicine 
and receive medical training. He returned 
to New Mexico and practiced medicine 
there for more than 50 years.
Prudence D’Angelo, NU 52
D’Angelo died on Sept. 18, 2012, at 
age 83. She was a pediatric nurse.
John Commerford, MD 53
Commerford died on Feb. 4, 2012. He 
served as a medical officer in the Public 
Health Service. He moved to St. Charles 
MO, where he was a partner in a private 
medical practice, practiced with Boonslick 
Medical Group, and had hospital privileges 
at St. Joseph’s Hospital where he served as 
chief of family practice and chief of staff. 
Andrew McCanse, MD 54
McCanse died on July 21, 2012. He served 
in the U.S. Army in Korea before return-
ing to Jewish Hospital for a surgical resi-
dency. He practiced general surgery for 
22 years and became the first chair of the 
Department of Surgery at the University of 
Missouri-Kansas City School of Medicine. 
Later he switched his specialty to occupa-
tional medicine, which he practiced until 
his retirement.
Richard Braun, MD 55
Braun died on Dec. 2, 2012. After medi-
cal school, Braun and his wife, Gertrude 
Braun, NU 54, served together at hospi-
tals in Ghana caring for patients and train-
ing nurses and medical students. Later 
he worked on the board of the Tennessee 
Health Care Campaign.
Patricia Simpson, NU 55
Simpson died on Jan. 2, 2012, in Memphis 
TN. She spent 42 years as a registered 
nurse and was a nursing home administra-
tor for 22 of them.
John Vander Woude, MD 78, HS 85
Vander Woude died on July 10, 2012. He 
was 58. After graduation, he entered the 
surgical residency program at Washington 
University School of Medicine. He moved 
to Texas for a cardiovascular surgery fel-
lowship and completed a fellowship in 
pediatric cardiac surgery at the University 
of California, San Francisco. He was direc-
tor of cardiothoracic surgery at Sanford 
USD Medical Center in Sioux Falls SD. He 
participated in surgical and medical mis-
sions in Kenya, China and Ecuador as well 
as volunteer work in his home community.
Ira C. Gall, MD, HS
Gall died on March 29, 2013. After 
completing his medical degree at the 
University of Cincinnati, Gall served as a 
physician in the U.S. Air Force before  
moving to St. Louis to complete a resi-
dency in obstetrics and gynecology. He 
went on to practice medicine at Barnes 
Hospital and later co-created Obstetrics 
and Gynecology, Inc., and Medicine 
Shoppe International. He was a philan-
thropist and strong community supporter.
F 
George Sato, MD 47, LA 96
Sato died on Feb. 5, 2013. In addition to 
his private pediatrics practice, Sato was a 
clinical professor at Washington University 
School of Medicine. He received the 
Washington University Medical Center 
Alumni Association Alumni Achievement 
Award in 1982.
Benje Boonshaft, LA 57, MD 61 
Boonshaft died on June 24, 2012, at  
age 76. An assistant professor emeritus  
of clinical medicine, he served in the  
U.S. Air Force Hospital during the  
Vietnam War. He helped build and co-
found Willowbrook Medical Center in 
Creve Coeur MO and was an internist  
for the St. Louis Blues.
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Cancer and  
personalized  
medicine BY  STEPHANIE  STEMMLER
At the forefront of personalized medicine, Washington University is 
conducting groundbreaking research to identify genetic and molecular 
changes that trigger cancer. We are translating that research into 
innovative diagnostic tools for individualized treatment. Our 
oncologists and radiologists are inventing better technologies to 
identify cancers and pinpoint their treatments. e result? Patients 
receive personalized care that is more effective and easier to tolerate.
 More than 350 Washington University physicians and 
researchers are engaged in cancer treatment and research. And 
the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and 
Washington University School of Medicine serves more than 50,000 
cancer patients annually. From prevention to care, education, research 
and outreach, Siteman Cancer Center is recognized as one of the great 
Comprehensive Cancer Centers in the United States by the National 
Cancer Institute. Our physicians help set national and global standards 
for cancer treatment as one of only 23 centers in the National 
Comprehensive Cancer Network. 
 Physicians at the School of Medicine and Siteman use a 
collaborative, multidisciplinary team approach to tackling cancer. 
rough investments in prevention, education, care and research, they 
say, the day will come when most cancers are preventable or treatable. 
Partner with us to reach that attainable goal.
We are redefining how cancer is diagnosed and treated. 
Alvin J. Siteman, left, had 
an extraordinary vision: 
Create an “institution 
of world-class cancer 
research, combined with 
compassionate cancer care, 
to provide longer life and 
lasting hope for generations 
to come.” Such partnerships 
are led by Timothy J. 
Eberlein, MD, director of the 
Siteman Cancer Center, the 
Spencer T. and Ann W. Olin 
Distinguished Professor and 
chair of the Department  
of Surgery at the School  
of Medicine.
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Wanting to make a difference in the fight 
against cancer, Harvey Saligman and his wife, 
Linda, saw an ideal opportunity. Diagnosed with 
multiple myeloma seven years ago, Saligman  
discovered that even though his disease was  
one of the most common types of blood cancer  
(lymphoma and leukemia among them), most 
research dollars went to other types of cancer. 
“I’m convinced that this particu-
lar cancer can be cured,” Saligman 
says. “We wanted to accelerate  
that time frame by supporting 
research efforts.”
e Harvey and Linda Saligman 
Multiple Myeloma Research Fund, 
established in 2009, is paying divi-
dends in terms of cancer research 
accomplishments. In the past year, 
two new drugs have received federal 
approvals to treat multiple myeloma, 
both the result of clinical trials in 
which Washington University was  
a leading research site.  
e university also has established a large 
myeloma tissue bank for ongoing research and  
is a member of the Multiple Myeloma Research 
Consortium — 13 U.S. academic centers focused 
on speeding the development of new therapies. 
“anks to support from the Saligmans, we’ve 
been able to get a critical mass of basic science 
researchers to focus on this disease and broaden 
our multifaceted effort to study the biology of 
multiple myeloma,” says Ravi Vij, MD, associate 
professor of medicine in the Division of Oncology. 
“It also enables us to conduct clinical trials, which 
are leading to new medications, such as the two 
that were recently approved.”
“We’ve already made great strides in improv-
ing the life expectancy of patients with multiple 
myeloma by helping to find new therapies as a 
result of this gi,” says Division of Oncology  
Chief John F. DiPersio, MD, PhD, the Virginia E. 
and Sam J. Golman Professor of Medicine  
in Oncology. 
 “It is so exciting to see the young scientists 
who actually are doing this work,” says Linda 
Saligman. “Because of their efforts, there is hope. 
Now that some of the research is also focused  
on the potential inherited aspect of this disease,  
there is hope for generations to come.”
Adds Harvey Saligman, “I’ve seen unbelievable 
advances in myeloma research here. e best part 
about going public about our own experience  
with this disease is that hopefully it will attract 
other people to give so that the momentum we 
have going can really make a difference.”
Linda and Harvey Saligman, center, support the multiple myeloma research of John F. DiPersio, MD, PhD, left, and Ravi Vij, MD.
Multifaceted efforts
“We’ve already made
great strides in improving
the life expectancy of
patients with multiple
myeloma by helping to
find new therapies as a
result of this gift.”
— JOHN F. DIPERSIO, MD, PHD
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As genomic discovery research finds more 
genes that are commonly altered, leading to vari-
ous types of cancer, treatment will focus not only 
on the body part being treated — breast, colon or 
prostate, for example — but also on the genetic 
blueprint of the disease. 
“Precision cancer medicine will mean that 
therapeutic decisions are based on the underlying 
mutations in each patient’s tumor,” 
says Elaine R. Mardis, PhD, co- 
director of e Genome Institute  
at Washington University.
More than 10 years ago, Institute 
scientists played a leading role in 
an international effort, the Human 
Genome Project, that decoded the 
complete sequence of human DNA. 
Today, the Institute is one of only 
three U.S. large-scale genomic cen-
ters funded by the National Institutes 
of Health (NIH).
In the fight against cancer, 
research at the Institute has breath-
taking consequences. In 2008, a team of researchers 
led by Timothy J. Ley, MD, the Lewis T. and 
Rosalind B. Apple Professor of Oncology, was  
the first to sequence the entire genome of a cancer 
patient, a woman diagnosed with acute myeloid 
leukemia (AML), thanks to a generous gi  
from Alvin J. Siteman. By comparing her cancer 
genome to similar data obtained by sequencing  
the patient’s healthy cells, the team identified 10 
mutated genes, setting the stage for using next- 
generation sequencing and analysis to decode  
hundreds of cancer cases.
Now Institute researchers have completely 
sequenced the DNA from paired tumor cells and 
healthy cells of more than 1,000 patients, effectively 
transforming the field of cancer genomics. e 
resulting data has had profound consequences  
for understanding the genetic basis of cancer, has 
identified key genes related to predicting outcome 
in several cancer types and has helped researchers 
consider how to make cancer therapy choices  
more precise, based on the mutations underlying 
individual tumors. 
Researchers say more funding could speed up 
whole genome sequencing for oncology. Six years 
ago, sequencing the whole genome of the AML 
patient took eight months. Today, it takes 28 hours. 
“I envision going from completing whole genome 
sequencing for 12 patients a year to hundreds of 
patients a day,” says Institute director Richard K. 
Wilson, PhD. “We need to make this process more 
efficient; you can’t do precision medicine without 
the basic genome work happening first.”
Timothy J. Ley, MD, left, Elaine R. Mardis, PhD, and Richard K. Wilson, PhD, use genome sequencing to understand the roots of cancer.
Seeking cancer’s roots
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Sitting at a kitchen table one night  
years ago, Jeffrey D. Milbrandt, MD, PhD, and 
Herbert “Skip” W. Virgin IV, MD, PhD, hashed 
out an idea that would help revolutionize medi-
cine. Milbrandt, the head of the department of 
genetics, and Virgin, the head of pathology and 
immunology, would combine their departments’ 
strengths in genetics and genomics and clinical 
laboratory testing to change the  
way diseases are diagnosed and 
patients are treated.
Melding their expertise, faculty, 
staff and resources, the two estab-
lished Genomics and Pathology 
Services, or GPS, a clinical genom-
ics testing service that provides a 
distinct road map for physicians  
on how best to treat a person’s  
specific disease based upon his or 
her own genetic variation. ey  
call it “precision or personalized 
medicine.”
 “is is not research, this is 
actual clinical care,” stresses Milbrandt, the  
James S. McDonnell Professor of Genetics.  
“We wanted to take genomics research and  
make it matter to patients today.”
Testing can identify gene mutations that impact 
the course of treatment. Once identified, available 
targeted drug therapies can be used. ey started 
with cancer and saw results almost immediately. 
ey found that one patient whose metastatic can-
cer was unresponsive to treatment had uncommon 
genetic mutations. When they offered a different 
class of drugs targeting those mutations, the 
tumors decreased in size within one month.
“We’ve proven we can impact care with this type 
of testing,” says Virgin, the Edward Mallinckrodt 
Professor of Pathology and Immunology. “We’ve 
done more than 1,000 cases of cancer already, and 
we’re finding mutations in those cancers that we 
didn’t expect to find.”
More resources could expand the testing plat-
form to include other genes. Funding also could 
help the team expand translational research trials 
to identify more targeted drug therapies and allow 
them to evaluate long-term patient outcomes. 
“We know what to do, and we’re moving 
beyond cancer to include sudden cardiac death, 
kidney disease and congenital birth defects, to 
name a few,” says Milbrandt.
Says Virgin, “e issue now is how fast can  
we do this and how many patients and diseases 
can we impact? is is a game-changer.”
Combined strengths
“The issue now is how fast
can we do [genome testing]
and how many patients and
diseases can we impact?
This is a game-changer. ”
— HERBERT “SKIP” W. VIRGIN,
MD, PHD
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The time is coming when all patients 
diagnosed with cancer will undergo a biopsy  
to identify the genetic fingerprint of their specific 
tumor, then receive tailored therapy to kill it. 
Groundbreaking research at Washington 
University School of Medicine is focused on 
attacking breast cancer at its genetic roots.  
Last year, a team of researchers, including 
Matthew Ellis, MB, BChir, PhD, 
chief of breast oncology at 
Washington University and the 
Anheuser-Busch Professor of 
Medical Oncology, discovered that 
breast cancer could be divided into 
four distinct types, all genetically 
different and all of which respond 
differently to various treatments.
“Not all breast cancers are alike. 
We know that certain medications 
are highly effective against broad 
types of breast cancer, but some 
women don’t respond well to  
those treatments,” Ellis says. 
“Instead of relying on a general ‘recipe’ for 
combating breast cancer, we need to individual-
ize treatment. We can do that by looking at the 
genetic components of each patient’s cancer.”
Already Ellis and other researchers have found 
that a form of breast cancer is genetically more 
similar to ovarian cancer than to breast cancer, 
which has striking implications for treatment 
strategies. Clinical trials here led to the develop-
ment of a diagnostic test now under review by  
the U.S. Food & Drug Administration. e test, 
currently for patients with hormone receptor- 
positive (HR+) early-stage breast cancer, classifies 
the cancer and the risk for recurrence based on  
the biologic components of each patient’s tumor. 
Ellis hopes the test will receive federal approval 
later this year. 
“Just in the last three years, the research has 
undergone dramatic advances,” says Jeanne Imbs 
Weitzel, who benefited from clinical trials. Gene 
analysis revealed that her cancer would likely not 
respond to chemotherapy following a mastectomy.  
Instead she was prescribed an estrogen-suppressing 
drug. “I wish every woman with breast cancer could 
experience this kind of personalized approach.  
Dr. Ellis gave me complete confidence that the 
treatment he prescribed was the most appropriate 
to combat my type of breast cancer.” Weitzel goes 
on to say, “Dr. Ellis is both brilliant and compas-
sionate; at every appointment I felt like his only 
patient. His caring approach has had a tremendous 
impact on my ability to heal.”  
Genetic fingerprints
“Discoveries here are
paving the way for
clinical trials and have the
potential to affect millions
of breast cancer patients.”
— MATTHEW  J. ELLIS,
MB, BCHIR, PHD
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Innovative imaging
It’s all about targeting in the battle against 
cancer. e arsenal to deliver highly targeted radi-
ation therapy for patients with prostate or bladder 
cancer will soon include new technology evaluated 
by Washington University radiation oncologists.
“ere’s no technology today that allows us 
to see inside a patient and treat a tumor at the 
same time. Instead, we use images obtained before 
radiation treatments to determine a 
tumor’s size and location,” says Jeff 
M. Michalski, MD, the Carlos Perez 
Professor of Radiation Oncology 
and vice chair of radiation oncol-
ogy. “e problem is that tumors 
can shi due to breathing or other 
movement. Just as neurosurgeons 
need to see a tumor as they remove 
it, radiation oncologists need to see 
the tumor while they radiate.”
Radiation oncologists here are 
evaluating a first-of-its-kind, com-
bined MRI imaging and intensity-
modulated radiation therapy 
(IMRT) system that provides continuous images 
of a tumor during treatments. Clinical trials, 
exclusive to the Alvin J. Siteman Cancer Center, 
are seeking to measure the value of the technology 
in cancer therapy.
“We have a long-standing reputation for inno-
vation in imaging and radiation therapy,” says 
Michalski, an internationally recognized radiation 
oncologist who has multiple studies under way  
to enhance treatment outcomes for prostate cancer 
patients. His latest clinical trials focus on combin-
ing radiation and hormone-suppression therapy 
(androgen deprivation) to try to pinpoint the  
optimal duration and amount of each while  
minimizing side effects.
Michael Pulitzer recognizes the strength of 
Michalski’s research and its impact on patients 
like him. He characterizes Washington University 
as having one of the best radiation therapy centers 
in the world. “e care I received was seamless,” 
says Pulitzer, who made an unrestricted donation 
to support Michalski’s research. “As a result,  
I have what could be called ‘grateful patient’  
syndrome. Dr. Michalski cured me, and I want  
to help him cure others.”
Michalski wants to collaborate with other 
researchers to find specific genes that impact treat- 
ment. “Each patient’s tumor biology may uniquely 
respond to radiation therapy, and we could tailor 
the treatment to maximize its benefits. We need  
to push ourselves beyond what we already know 
because that results in better, more effective  
cancer treatments and outcomes,” he says.
“Just as neurosurgeons
need to see a tumor as
they remove it, radiation
oncologists need to see the
tumor while they radiate.”
— JEFF M. MICHALSKI, MD
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“I don’t have time for cancer,” says Ina 
Sachar, who has lived with cancer for 20 years. 
Instead, the 66-year-old St. Louis resident has four 
grandchildren to spoil and places she wants to 
travel. She embodies the strength of the human 
spirit and the advances made to eradicate cancer.
Sachar has battled cancer since 1993 — first 
breast cancer, then ovarian, endometrial and 
colon cancer. While the ovarian 
cancer has recurred, she has fought 
back each time with new drug 
therapies that have become available 
over the past two decades.
“I’ve been the beneficiary of 
targeted therapies and the research 
that’s been done at Washington 
University and the Siteman Cancer 
Center,” Sachar says.
e university currently has 
35 different gynecologic oncol-
ogy clinical trials open and active. 
Washington University researchers 
are among the largest contribu-
tors to a national consortium, the Gynecologic 
Oncology Group. 
“We have very good therapies because of all 
the clinical trials and genomic research done at 
Washington University,” says David G. Mutch, 
MD, chief of the division of gynecologic oncology, 
where six oncologists all work together. “We can 
practice state-of-the-art care because we are at a 
great university where all areas are excellent.”
Because of their record of excellence in patient 
care and research, Washington University and 
Siteman Cancer Center received the National 
Cancer Institute’s first Specialized Program of 
Research Excellence (SPORE) grant to accelerate 
research into causes and treatments for endo-
metrial cancer. e multi-year grant, awarded  
in 2010, is showing results.
“We’ve identified more accurate, cost-effective 
ways to screen patients for an inheritable form of 
endometrial cancer that could be available to the 
public in the next year or so,” says Mutch, the  
Ira C. and Judith Gall Professor of Obstetrics  
and Gynecology. “We’re also learning more about 
the molecular makeup of this cancer and the  
gene mutations that impact the success or failure 
of treatment options.”
Research has correlated a genetic link between 
ovarian and breast cancer and between inherited 
versions of endometrial cancer and colon cancer. 
More effective, targeted treatments for gynecologic 
cancers might benefit all cancer patients.
Says Sachar, “e reason to fund research like 
this is that they will find secrets to many cancers.”
Finding new therapies
“We have very good
therapies because of
all the clinical trials and
genomic research done at
Washington University.”
— DAVID G. MUTCH, MD
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Cancer and Personalized Medicine
	 n Endowed professorships for specific departments  
 or diseases  
 n Endowed research funds for specific departments  
 or diseases 
 n Endowed gis to be recognized by naming an institute,  
 center or research laboratory
 n Annual or endowed fellowship support  
 for physician-scientists
 n Expendable support for three- to five-year pilot projects
 n Annual unrestricted support
The Brain   
Diabetes, Heart Disease, and Obesity  
Infectious Diseases and Global Health
The Next Generation:  
Professors, Graduate Fellows, and Students  
The Annual Fund
Together,  
 we can change lives.
We are redefining how cancer is diagnosed and treated.
Please consider funding this or other opportunities to
advance human health.
For information
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At the top
On May 18, 2013, Gosia Borchardt, a 
Washington University nurse anesthetist at 
Barnes-Jewish Hospital, fulfilled a long-time 
goal: She reached the top of the world, the 
summit of Mt. Everest. Her quest to climb 
the highest peaks on all seven continents 
— the Seven Summits — has taken her  
to the top of Mt. Kilimanjaro in Africa  
(2007), Mt. Elbrus in Europe (2009) and  
Mt. Aconcagua in South America (2010).  
An injury on the Aconcagua climb resulted 
in thoracic outlet syndrome (TOS), surgery 
by Washington University vascular surgeon 
Robert Thompson, MD, and a long recovery. 
The Everest climb was the culmination of 
five years of planning and training. On her 
way back to base camp, she posted on 
Facebook: “I still can’t believe I made it all 
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Lung cancer therapy
When is it best to use targeted 
radiation, and when should 
physicians advocate minimally 
invasive surgery? Research will 
provide a better basis for making 
the optimal decision in each case. 
This scan of a patient’s body shows 
the paths of the radiation beams 
planned for his therapy. The 
precise convergence of multiple 
beams amplifies their effects on 
the tumor. For more on this story, 
please turn to page 20.
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